title: Tuberculosis deaths: are we measuring accurately?
abstract: Death among tuberculosis patients is one of the major reasons for non-attainment of 85% treatment success target set by World Health Organization. In this short paper, we evaluated whether the overall mortality rate in pulmonary tuberculosis is being affected by other comorbid conditions. All new smear positive pulmonary tuberculosis patients (N =336), who started their treatment at the chest clinic of the Penang General Hospital, between March 2010 and February 2011, were followed-up until December 2011. Tuberculosis treatment outcomes were reported according to six treatment outcome categories recommended by World Health Organization. The outcome category 'died' was defined as 'a patient who died due to tuberculosis or other cause during tuberculosis treatment'. Our findings showed that out of 336 smear positive pulmonary tuberculosis patients, 59 (17.6%) died during treatment (mortality rate = 1.003 cases per 1000 person-days of follow-up). Among the deceased patients, the mean age was 55.8 years (SD =16.17) and 49 were male. According to the mortality review forms, 29 deaths were tuberculosis-related, while the remaining 30 patients died due to reasons other than tuberculosis. Cerebrovascular accident (n =7), septicaemia shock (n =4) and acute coronary syndrome (n =4) were the most common non-tuberculosis related reasons for mortality in the patients. If the 30 patients, for whom tuberculosis was incidental to death, are excluded from the final cohort, the proportion of patients in the 'died' outcome category could be reduced to 9.5%. The treatment outcome criterion (i.e., died) set by World Health Organization has limitations. Therefore, it requires improvement for more objective evaluation of the performance of the National Tuberculosis Program.
authors.affiliation: Department of Pharmacy, The Islamia University of Bahawalpur, Punjab, Pakistan ; Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Atif
authors.affiliation: Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
authors.forename: Syed Azhar Syed
authors.initials: SA
authors.lastname: Sulaiman
authors.affiliation: Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
authors.forename: Asrul Akmal
authors.initials: AA
authors.lastname: Shafie
authors.affiliation: Department of Pharmacy, The Islamia University of Bahawalpur, Punjab, Pakistan.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Qamar Uz Zaman
authors.affiliation: Department of Pharmacology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Asif
references.citation: BMC Infect Dis. 2009 Dec 31;9:217
references.pmid: 20043847
references.citation: Int J Tuberc Lung Dis. 2011 Feb;15(2):257-62, i
references.pmid: 21219691
references.citation: Int J Tuberc Lung Dis. 2006 Aug;10(8):857-63
references.pmid: 16898369
references.citation: BMC Infect Dis. 2010 Aug 27;10:258
references.pmid: 20799975
references.citation: Int J Clin Pharm. 2012 Aug;34(4):506-9
references.pmid: 22706597
references.citation: Thorax. 2008 May;63(5):440-6
references.pmid: 17615085
references.citation: BMC Infect Dis. 2014 Jul 19;14:399
references.pmid: 25037452
references.citation: Swiss Med Wkly. 2002 Sep 7;132(35-36):517-22
references.pmid: 12506334
references.citation: Clin Med (Lond). 2003 Jan-Feb;3(1):57-61
references.pmid: 12617417